Has Santanu Biswas, MD received payments from drug or device companies?

Yes. Drug and device makers reported $30,083 in general payments to Santanu Biswas, MD across 73 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Santanu Biswas, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Santanu Biswas, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Santanu Biswas, MD

Cardiovascular Disease · Seattle, WANPI 1639138944

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 91.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $18,407 and has fallen 52.1% since, to $8,822 in 2025. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,083in general payments, 2019–2025

Across 73 payments — averaging $412.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$27K
Edwards Lifesciences$967
Heartflow, Inc.$833
Vifor (international) Ltd.$533
Siemens Medical Solutions USA, Inc.$177
Alnylam Pharmaceuticals Inc.$40
plus $87 from 4 others

$39,922in research payments, 2019–2025

Across 6 payments — averaging $6653.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$40K

What the payments were for

Consulting fees$17,03357%
Speaking & faculty fees$3,87513%
Travel & lodging$5,22817%
Food & beverage$3,94713%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	48	$27,446
Edwards Lifesciences	14	$967
Heartflow, Inc.	3	$833
Vifor (international) Ltd.	1	$533
Siemens Medical Solutions USA, Inc.	2	$177
Alnylam Pharmaceuticals Inc.	1	$40
Bardy Diagnostics, Inc.	1	$25
Novo Nordisk	1	$23
Boston Scientific	1	$21
Lantheus Medical Imaging, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

MitraClip$17,080
THORATEC HEARTMATE 3 LVAS IMPLANT KIT$3,500
TRICLIP$3,439
FFRct$833
MitraClip System$223
SAPIEN 3 Ultra RESILIA$207
AMPLATZER$184
SOMATOM go.Top$143

How this compares

$30,083 in reported general payments places this provider in the 95th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington →

Medicare billing

Part B allowed, 2024

$235,010

Medicare patients

2,659

Services billed

5,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	208	$255,660
XareltoRivaroxaban	30	$40,462
Repatha SureclickEvolocumab	15	$15,534
EntrestoSacubitril/Valsartan	13	$14,476
Metoprolol Succinate	267	$3,505
Bumetanide	52	$2,881
Flecainide Acetate	42	$2,089
Atorvastatin Calcium	208	$1,967
Potassium Chloride	66	$1,766
Rosuvastatin Calcium	76	$1,594
Losartan Potassium	95	$1,382
Furosemide	180	$1,243
Amlodipine Besylate	143	$1,108
Carvedilol	74	$1,061
Diltiazem 24hr Er (Cd)Diltiazem Hcl	37	$1,019

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Seattle

Mariko HarperSeattle$246K
Gary OppenheimSeattle$153K
Kelley BranchSeattle$103K
Erik WissnerSeattle$67K
Younghoon KwonSeattle$66K
Aron BenderSeattle$60K
Vidhushei YogeswaranSeattle$55K
Bhanu GuptaSeattle$27K
Michael LongoSeattle$22K
Oana PetrescuSeattle$13K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →